IXICO wins £1.5 million of Alzheimer’s imaging and biomarker work

IXICO ($IXI) secured two Alzheimer’s-related contracts with a combined value of approximately £1.5 million. One covers neuroimaging management and analysis for a biotechnology client’s Phase 2b study, with revenue expected over roughly three years. The other extends work for an international life-sciences diagnostics customer, using IXICO’s imaging platform to support validation and regulatory submissions for a blood-based Alzheimer’s biomarker test.

Revenue from the diagnostics extension is expected within one year, giving the awards different conversion schedules. The contracts add work in both drug development and diagnostics, expanding the potential applications of IXICO’s imaging infrastructure. The customers were not identified, and the announcement did not disclose upfront cash payments. Supporting a test’s validation and regulatory process does not establish that the test has received approval or that the clinical study will succeed.

Sources:

• RNS via Investegate
• RNS via Investegate — announcement index